Logo

Biotheus Collaborates with BioNTech for the Development and Commercialization of PM8002 to Treat Multiple Solid Tumor Indications

Share this
Biotheus

Biotheus Collaborates with BioNTech for the Development and Commercialization of PM8002 to Treat Multiple Solid Tumor Indications

Shots:

  • As per the agreement, Biotheus will receive an up front payment of $55M & is eligible to receive an aggregate of $1B in development, regulatory & sales-based milestone payments, plus tiered royalties. The transaction is expected to close by Q4’23
  • In return, BioNTech has received the license to develop, manufacture & commercialize PM8002 globally, except Greater China for which Biotheus retains the rights. Additionally, PM8002 is currently being evaluated in a P-II trial as monotx. or in combination with CT in patients with advanced solid tumors
  • PM8002 is a bispecific Ab that contains humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused to an anti-VEGF-A IgG1 Ab containing Fc-silencing mutations

Ref: PRNewswire  | Image: Biotheus

Related News:- Biotheus Entered into a License and Collaboration Agreement with Hansoh Pharma for PM1080

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions